In a chapter for United Nations Development at a Crossroads, published by New York University's Center on International Cooperation, Laurie Garrett outlines five existential challenges facing global health today, writing that leaders and institutions that are key to global health have barely recognized these threats, much less developed policy solutions or adaptations.

Peter Orszag writes that the federal government can learn from the evidenced-based focus of some organizations that are targeting childhood obesity.

Peter Orszag wants regulators to watch out for excessive consolidation in local hospital markets as Medicare's shift to value-based payments puts pressure on health care providers to merge and raise fees for private insurers.

Yanzhong Huang explains that "In Asia, the capacity of NGOs to contribute to public health, both within individual countries and at the regional level, has steadily expanded."

Thomas Bollyky describes the crisis emerging over access to treatment for diabetes, cancers, and other non-communicable diseases (NCDs). Bollyky argues that this crisis could transform the global response to NCDs as the last treatment access crisis transformed the international approach to HIV/AIDS.

In this Working Paper, the author examines the controversy surrounding the publication of two H5N1 flu–transmission studies and offers lessons learned for future dual-use research.

CFR Senior Fellow for Global Health Laurie Garrett explains the conundrum of dual-use research of concern (DURC), in which the same experiments that allow scientists to understand pandemics can also create dangerous pathogens. Combined with advances in synthetic biology and increasingly affordable technologies, there is the possibility for a true biology revolution.

Without a more transparent international research and information-sharing system, Middle East respiratory syndrome (MERS) could spread far beyond the bounds of the region for which it is named, write Laurie Garrett and Maxine Builder.

Yanzhong Huang argues that while Chinese growth has been impressive, it's singular focus on economic development has negatively affected health, environment, and social areas.

Thomas Bollyky discusses the brewing fight over intellectual property and access to noncommunicable disease medicines in low- and middle-income countries and a potential way forward.

Laurie Garrett warns that the MERS virus outbreak must be taken seriously.

A new virus discovered in Saudi Arabia is raising deep concerns over its lethality. An intellectual property dispute could be impeding efforts to contain it, writes CFR's Laurie Garrett.

Dr Margaret Chan, Director-General of the World Health Organization, commends the work of the World Health Assembly in closing remarks at the Sixty-sixth World Health Assembly in Geneva Switzerland, May 27, 2013.

CFR Senior Fellow Thomas Bollyky argues that new strategies are needed to address the latest treatment-access crisis over patented medications, particularly as noncommunicable diseases continue to rapidly emerge in low- and middle-income countries.

Laurie Garrett and Maxine Builder offer three recommendations for how the World Health Organization can adapt to an uncertain economic and political environment, without putting the world at risk of a disease outbreak.

In his testimony before the Congressional-Executive Commission on China, Yanzhong Huang discusses China's recent public health crises. He focused on two areas: encouraging further government transparency and emboldening civil society to help enact policy changes.

Peter Orszag argues that giving health-care providers a fixed payment for each Medicare beneficiary could provide a path forward between competing views of health care reform offered by Republicans and Democrats.

The H7N9 virus, a new strain of the bird flu in China, has so far claimed twenty-two victims and officials are watching its spread closely.

Read full answer

Laurie Garrett offers a detailed account of how the H7N9 virus emerged and describes the two possible paths it may now follow, by pulling from her own experiences in the SARS epidemic ten years ago and reflecting on parallels between the two.

Thomas Bollyky writes about how national patent laws are affecting pharmaceutical cost differentials around the world.